Sign in
Taking peoplePhase 1/2

SENS-601 injected into the inner ear for children with GJB2-related hearing loss

Tests SENS-601 injected into the cochlea in children with GJB2-related hearing loss.

Key facts

Who runs it
Sensorion
Where
France1 site in 1 countryChoose a country to see its sites
Registry title
A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene.
Status
Recruiting
Phase
Phase 1/2
People taking part
6 people, planned
Started
16 Oct 2026
Expected to end
15 Dec 2034
Type of study
Interventional
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for young children with severe hearing loss from birth in both ears, caused by changes in both copies of the GJB2 gene. SENS-601 is injected into the inner ear (cochlea).

Age
6 months to 6 years at the time of SENS-601 dosing (corrected age if born early)
Sex
Boys and girls
Disease stage
Severe sensorineural hearing loss (inner ear hearing loss) in both ears, present from birth. The cochlea and inner ear canals must be documented as normal.
Earlier treatment
Children who had a gene therapy in an earlier study cannot join. A past or current cochlear implant in the ear to be treated is not allowed. No other study drugs within the time set by the protocol (at least the last 12 weeks).
Biomarker or test result
Pathogenic or likely pathogenic changes in both copies of the GJB2 gene, confirmed by DNA sequencing.

Main reasons for not taking part

  • Hearing loss from other genes or other causes, such as malformed cochlea, hearing loss in one ear only, or a syndrome
  • A history of chronic, acute or major disease
  • Unable to have corticosteroids, immune-suppressing treatment, the surgery or anaesthesia
  • Needing a live vaccine from screening up to 3 months after SENS-601
  • Allergy to SENS-601 ingredients, SPHYNX parts or other study medicines

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Are males or females aged ≥6 months to ≤6 years (corrected age in case of premature birth) at the time of SENS-601 administration
  • Have a diagnosis of congenital bilateral severe sensorineural hearing loss
  • The participant’s legally authorized representative (LAR) must have given written informed consent and any authorization as required per local law and be able to comply with all study requirements
  • Have biallelic pathogenic or likely pathogenic GJB2 variation(s), confirmed by DNA sequencing
  • Have a documented normal cochlea and internal auditory canals
  • Are affiliated with or is a beneficiary of a health care system
  • Have eligibility confirmed by the Principal Investigator after a local multidisciplinary evaluation

Who cannot take part

  • Require vaccination with a live attenuated vaccine from Screening up to 3 months following SENS-601 administration
  • Plan to use other investigational drugs or has used other investigational drugs within 5 half-lives of SENS-601 administration, or until the expected pharmacodynamic effect has returned to baseline or enrolled in a clinical study with an investigational drug within the last 12 weeks, whichever is longer
  • Have been dosed in a previous gene therapy clinical study
  • Have a prior or current cochlear implant in the ear to be treated with SENS-601
  • Have a contraindication to corticosteroid therapy and/or immunosuppressive or immunomodulatory therapy
  • Have a history of chronic, acute, or major disease
  • Have any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the participant or would preclude the participant from successful completion of the study or might interfere with the evaluation of study treatment
  • Have a history of documented allergic reactions or acute hypersensitivity reactions attributed to SENS-601 excipients or impurities or SPHYNX components or any other medications used in this study
  • Have hearing loss caused by developmental disorders (eg, cochlear aplasia or hypoplasia) or other diseases or risk factors
  • Have other causes of hearing loss, such as unilateral hearing loss, chronic conductive hearing loss, malformation syndrome, or syndromic hearing loss
  • Have a contraindication to the planned surgery, a contraindication to anesthesia or increased anesthesiologic risk, or a history of therapy known as ototoxic for an extended period
  • Have documented other causes of congenital bilateral hearing loss linked to mutations in genes other than GJB2
  • Are participating in any other interventional clinical study
  • Are anticipated to be noncompliant with the Protocol requirements, in the opinion of the Investigator
  • Have hearing loss due to any other cause that would impact negatively the response of hair cell function

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Part 1: assess the safety and tolerability of SENS-601, the SPHYNX administration system following unilateral injection of SENS-601 into the cochlea using the SPHYNX injection system.

Read full original descriptionShow less

Part 2: assess the efficacy of SENS-601 following bilateral intracochlear injection.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability.
Plain-language title
SENS-601 injected into the inner ear for children with GJB2-related hearing lossGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
19 October 2026